Takafumi Sato
Toyonaka, 5610825, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19.
Journal: Journal of medicinal chemistry
Published: July 05, 2025
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa.
Journal: The Journal of antimicrobial chemotherapy
Published: March 14, 2025
Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal Pseudomonas aeruginosa infection via inhibition of toxin translocation by the type III secretion system.
Journal: Antimicrobial agents and chemotherapy
Published: September 13, 2024
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Journal: Journal of medicinal chemistry
Published: March 30, 2022
Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure-Activity-Relationships and In Vitro and In Vivo Activities.
Journal: ACS infectious diseases
Published: February 03, 2022
A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
Journal: Bioorganic & medicinal chemistry
Published: March 29, 2021
In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia.
Journal: Antimicrobial agents and chemotherapy
Published: July 07, 2020
Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model.
Journal: Antimicrobial agents and chemotherapy
Published: June 16, 2020
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014).
Journal: Journal of global antimicrobial resistance
Published: May 02, 2020
Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study.
Journal: JAC-antimicrobial resistance
Published: April 30, 2020
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 15, 2019
Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Journal: The Journal of antimicrobial chemotherapy
Published: November 17, 2018
Last Updated: 09/26/2026